secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2023-04-28T23:59:59+00:00
Accession:  0001558370-23-007158
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala subsidiary awarded $15M CIRM grant for KPI-012 PCED Phase 2b trial
-----------------------------------------------------------------------

- CIRM awarded Combangio a $15M grant to support KPI-012 for persistent corneal epithelial defect.
- Grant funds the CHASE Phase 2b trial, product characterization, and analytical development.
- Part of the award is upfront; remainder upon achieving specified milestones.
- Combangio must meet a co-funding requirement; Kala committed to provide necessary funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023007158/0001558370-23-007158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023007158/kala-20230428x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-007158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer